Purinergic Signalling

, Volume 9, Issue 2, pp 135–143

The CD39-adenosinergic axis in the pathogenesis of renal ischemia–reperfusion injury

  • Veena Roberts
  • Bo Lu
  • Siddharth Rajakumar
  • Peter J. Cowan
  • Karen M. Dwyer
Review Article

DOI: 10.1007/s11302-012-9342-3

Cite this article as:
Roberts, V., Lu, B., Rajakumar, S. et al. Purinergic Signalling (2013) 9: 135. doi:10.1007/s11302-012-9342-3

Abstract

Hypoxic injury occurs when the blood supply to an organ is interrupted; subsequent reperfusion halts ongoing ischemic damage but paradoxically leads to further inflammation. Together this is termed ischemia–reperfusion injury (IRI). IRI is inherent to organ transplantation and impacts both the short- and long-term outcomes of the transplanted organ. Activation of the purinergic signalling pathway is intrinsic to the pathogenesis of, and endogenous response to IRI. Therapies targeting the purinergic pathway in IRI are an attractive avenue for the improvement of transplant outcomes and the basis of ongoing research. This review aims to examine the role of adenosine receptor signalling and the ecto-nucleotidases, CD39 and CD73, in IRI, with a particular focus on renal IRI.

Keywords

Ischemia–reperfusion injuryRenal transplantPurinergic signallingAdenosine receptorEctonucleotidase

Abbreviations

ADO

Adenosine

ADP

Adenosine diphosphate

AMP

Adenosine monophosphate

ATP

Adenosine triphosphate

cAMP

3′-5′-Cyclic adenosine monophosphate

EC

Endothelial cells

ENT1

Equilibrative nucleoside transporter 1

HIF

Hypoxia inducible factor

IP

Ischemic preconditioning

IRI

Ischemia–reperfusion injury

NPP

Nucleotide pyrophosphatase/phosphodiesterase

PD-1

Programmed death-1

PTC

Proximal tubule cells

S1P1R

Sphingosine-1-phosphate receptors

SK-1

Sphingosine kinase-1

Treg

Regulatory T cells

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Veena Roberts
    • 1
  • Bo Lu
    • 1
  • Siddharth Rajakumar
    • 1
  • Peter J. Cowan
    • 1
  • Karen M. Dwyer
    • 1
  1. 1.St. Vincent’s Hospital MelbourneImmunology Research CentreMelbourneAustralia